Can liver stiffness measurement accurately predict disease progression and clinical outcome in patients with metabolic dysfunction-associated steatotic liver disease and bridging fibrosis or cirrhosis?  

作　　者：Diederick J.van Doorn Adriaan G.Holleboom R.Bart Takkenberg Joanne Verheij Marten A.Lantinga 

机构地区：[1]Department of Gastroenterology and Hepatology,Amsterdam UMC,University of Amsterdam,Amsterdam Gastroenterology Endocrinology Metabolism,Amsterdam,The Netherlands [2]Department of Vascular Medicine,Internal Medicine,Amsterdam UMC,University of Amsterdam,Amsterdam Gastroenterology Endocrinology Metabolism,Amsterdam,The Netherlands [3]Department of Hepatopancreatobiliary Pathology,Amsterdam UMC,University of Amsterdam,Amsterdam,The Netherlands

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第6期912-915,共4页肝胆外科与营养（英文）

摘　　要：Diederick J.van Doorn1,Adriaan G.Holleboom2,R.Bart Takkenberg1,Joanne Verheij3,Marten A.Lantinga11Department of Gastroenterology and Hepatology,Amsterdam UMC,University of Amsterdam,Amsterdam Gastroenterology Endocrinology Metabolism,Amsterdam,The Netherlands;2Department of Vascular Medicine,Internal Medicine,Amsterdam UMC,University of Amsterdam,Amsterdam Gastroenterology Endocrinology Metabolism,Amsterdam,The Netherlands;3Department of Hepatopanc Metabolic dysfunction-associated steatotic liver disease(MASLD)-until recently termed non-alcoholic fatty liver disease(NAFLD)-is a rising cause of chronic liver disease with an estimated global prevalence of 30%(1).

关 键 词：CIRRHOSIS liver stiffness steatotic liver disease 

分 类 号：R575[医药卫生—消化系统]